Detalhe da pesquisa
1.
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
N Engl J Med
; 389(11): 998-1008, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37356033
2.
MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH.
Gut
; 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418210
3.
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
Haematologica
; 106(9): 2354-2363, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054121
4.
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Lancet Oncol
; 18(10): 1327-1337, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28843768
5.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Lancet Oncol
; 17(1): 27-38, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26671818
6.
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
Nat Med
; 29(7): 1782-1792, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37355760
7.
Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis.
Aliment Pharmacol Ther
; 58(10): 1005-1015, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37718721
8.
Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE).
Cancer
; 118(4): 1083-90, 2012 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21800287
9.
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study.
Breast Cancer Res Treat
; 135(3): 875-83, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22923238
10.
Carfilozomib versus bortezomib for relapsed or refractory myeloma - Authors' reply.
Lancet Oncol
; 17(4): e126, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27300661
11.
Use and evaluation of a CD-ROM-based decision aid for prostate cancer treatment decisions.
Behav Med
; 36(4): 130-40, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-21186436
12.
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
J Hematol Oncol
; 13(1): 48, 2020 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32393328
13.
Estimating variance parameters from multivariate normal variables subject to limit of detection: MLE, REML, or Bayesian approaches?
Stat Med
; 28(20): 2605-16, 2009 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19598183
14.
Laplace's approximation for relative risk frailty models.
Lifetime Data Anal
; 15(3): 343-56, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19184420
15.
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
Blood Cancer J
; 9(3): 23, 2019 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796199
16.
Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
Nat Med
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438737
17.
Are health-care relationships important for mammography adherence in Latinas?
J Gen Intern Med
; 23(12): 2024-30, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18839258
18.
Toxicological analysis of low-nicotine and nicotine-free cigarettes.
Toxicology
; 249(2-3): 194-203, 2008 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-18599178
19.
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
Leuk Lymphoma
; 59(6): 1364-1374, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28937327
20.
Disparities despite coverage: gaps in colorectal cancer screening among Medicare beneficiaries.
Arch Intern Med
; 165(18): 2129-35, 2005 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-16217003